An interventional study of WARD-CSS (Wireless Assessment of Respiratory and Circulatory Distress - Clinical Support System) in Patient Deterioration, Patient Monitoring and Clinical Deterioration, sponsored by Eske Kvanner Aasvang. Not yet recruiting at 5 sites in 4 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-05.
Sponsored by Eske Kvanner Aasvang · Not applicable, Interventional, and Supportive care
Hospital patient monitoring in Europe is often intermittent, which can delay detection of clinical deterioration during hospitalization and after discharge. The WARD-EU study aims to describe current monitoring practices and to evaluate the feasibility, acceptability, and usability of the WARD-CSS (Wireless Assessment of Respiratory and Circulatory Distress - Clinical Support System), an algorithm-based continuous monitoring system. The study seeks to assess whether WARD-CSS can be integrated into routine hospital and post-discharge care to support earlier detection of patient deterioration and improved patient monitoring.
The WARD-EU study is a multinational, multicentric, mixed-methods observational investigation conducted across four European countries. The study is designed to explore variation in hospital patient monitoring practices and to evaluate the implementation potential of an algorithm-based continuous monitoring system across different healthcare settings.
The study consists of two sequential phases. Phase 1 (pre-implementation) focuses on mapping existing monitoring practices for adult patients admitted for medical or surgical conditions with an expected hospital stay of at least two days. Data will be collected using structured questionnaires administered to patients and nursing staff to characterize monitoring frequency, workflows, perceived safety, and user experience within participating healthcare systems.
Phase 2 (post-implementation) evaluates the integration of the WARD-CSS (Wireless Assessment of Respiratory and Circulatory Distress - Clinical Support System) into routine clinical practice. WARD-CSS combines wearable wireless sensors for continuous vital sign monitoring with an application incorporating clinically modelled algorithms designed to detect early signs of respiratory and circulatory deterioration while reducing unnecessary alerts. During this phase, the system will be used for in-hospital monitoring and, where feasible, extended to post-discharge home monitoring.
Data collection in Phase 2 will include questionnaires from healthcare professionals and patients to assess usability, feasibility, and acceptability of the system, as well as descriptive analysis of system-generated vital sign data, monitoring adherence, and measurement frequency. Complications occurring within 30 days following hospital discharge will be recorded. Qualitative feedback will be used to identify facilitators and barriers to implementation, including technological challenges, workflow integration, and patient compliance, particularly in home-monitoring settings.
The study will enroll adult patients and healthcare professionals from participating centers. Participants may be involved during hospitalization and, for selected patients, during home monitoring following discharge, with follow-up up to 30 days. Data will be analyzed descriptively using appropriate parametric and non-parametric methods to identify patterns and variability across countries and care settings.
The study will be conducted in accordance with the Clinical Study Protocol, ICH-GCP, ISO 14155, the Declaration of Helsinki, and applicable national regulatory requirements. Ethics approval will be obtained from relevant committees in all participating countries, and data handling will comply with the General Data Protection Regulation and local data protection laws.
47 studies on the registry are indexed under Clinical Deterioration; 15 are open to participants now.
This study's planned enrollment of 1,240 is above the median of 375 across 21 interventional studies indexed under Clinical Deterioration.
Browse Clinical Deterioration studies →Eske Kvanner Aasvang is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive continuous monitoring using the WARD-CSS system during hospitalization and, where applicable, at home after discharge. Pre-implementation baseline data will be collected prior to WARD-CSS rollout for within-subject comparisons of usability, workflow integration, patient experience, adherence, and alert response.
Device: WARD-CSS (Wireless Assessment of Respiratory and Circulatory Distress - Clinical Support System)
Participants in Phase 2 will be monitored using the WARD-CSS system, which combines wearable wireless vital sign sensors with an application that applies clinically modeled algorithms to detect early signs of respiratory and circulatory deterioration. The system provides real-time data to healthcare professionals, reduces unnecessary alerts, and supports both in-hospital and, where feasible, post-discharge home monitoring.
Evaluation of monitoring practices and WARD-CSS feasibility
Implementation of the WARD-CSS continuous monitoring system will be evaluated using structured surveys administered to healthcare professionals and patients. Surveys include: Self-developed questionnaires for patients and healthcare professionals administered before and after implementation to assess perceived system performance, usability, workflow integration, and implementation challenges. mHealth App Usability Questionnaire (MAUQ) administered after implementation to assess usability (total and subscale scores calculated according to scoring guidelines; higher scores indicate better usability). Normalization Measure Development Questionnaire (NoMAD) administered after implementation to assess implementation integration into routine practice (total score calculated according to scoring guidelines; higher scores indicate greater normalization/integration). For each instrument, mean total scores will be reported based on their respective validated scoring systems.
Time frame: From enrollment to up to seven days from either admission in the in-hospital cohort or discharge to home in the home monitoring cohort.
Patient experience and usability
Patient-reported comfort, perceived safety, and usability of monitoring will be assessed using structured self-developed questionnaires. Surveys will evaluate: * Physical comfort during monitoring * Perceived safety while being monitored * Ease of use and overall usability of the monitoring system Responses will be scored using predefined scales. Higher scores will indicate more positive patient experience (greater comfort, safety, and usability). Assessments will be conducted during standard monitoring practice (pre-implementation) and during WARD-CSS-supported monitoring (post-implementation), including home monitoring where applicable.
Time frame: From enrollment to up to seven days from either admission in the in-hospital cohort or discharge to home in the home monitoring cohort.
Patient Compliance Rate
Percentage of prescribed monitoring time during which the WARD-CSS device was actively worn and transmitting valid data. Unit of Measure: % of prescribed monitoring time
Time frame: From enrollment up to seven days from either admission in the in-hospital cohort or discharge to home in the home monitoring cohort.
Incidence of complications
The incidence of severe adverse events (SAEs) will be assessed according to predefined criteria outlined in the WARD Outcome Manual (Appendix 12). SAEs include clinically significant events such as life-threatening deterioration, unplanned intensive care unit admission, or other events meeting SAE criteria as defined in the study manual. The number and proportion of participants experiencing at least one SAE will be recorded for: Patients receiving standard monitoring (pre-implementation) Patients monitored using the WARD-CSS system during hospitalization and/or home monitoring (post-implementation)
Time frame: From enrollment until 30 days post-discharge.
Healthcare Professional Response to Alerts
Proportion of system alerts responded to using in-app response buttons: attend, snooze etc. Unit of Measure: % of alerts responded per patient
Time frame: From enrollment up to seven days from either admission in the in-hospital cohort or discharge to home in the home monitoring cohort.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Dec 2027, 20 months later.
Of 15 interventional studies with no phase under Clinical Deterioration, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's planned 20 months is close to that.
Clinical Deterioration covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eske Kvanner Aasvang